Product Code: ETC6188579 | Publication Date: Sep 2024 | Updated Date: Apr 2025 | Product Type: Market Research Report | |
Publisher: 6Wresearch | Author: Shubham Deep | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
The Australian pneumonia therapeutics market is primarily focused on antibiotics, antivirals, and other medications used to treat pneumonia. The growing prevalence of respiratory infections, combined with the increasing incidence of antibiotic-resistant pneumonia, is driving the demand for new and more effective treatments. In particular, the market is witnessing the development of advanced biologic drugs and novel antibiotics aimed at treating pneumonia caused by resistant bacteria, which is a significant concern for the healthcare system.
The pneumonia therapeutics market in Australia is experiencing growth due to advancements in antimicrobial treatments, including the development of novel antibiotics that target resistant strains of pneumonia-causing bacteria. The rise of antimicrobial resistance is prompting increased research into new therapeutic options. Additionally, the growing number of elderly and immunocompromised individuals in Australia is driving demand for more effective treatments to reduce the burden of pneumonia.
The pneumonia therapeutics market in Australia faces challenges related to antibiotic resistance, which makes treatment of pneumonia more complex and requires the development of new antimicrobial agents. Additionally, there are rising concerns about the overuse of antibiotics in treating pneumonia, leading to a growing demand for more targeted therapies. Regulatory challenges and the high cost of developing new pneumonia therapeutics also pose significant barriers to market growth.
The pneumonia therapeutics market is a stable investment segment with consistent demand across hospitals and clinics. There`s room for innovation in antibiotics, particularly in combating resistant strains. Investments in combination therapies, long-acting injectables, and precision medicine approaches can further diversify portfolios and ensure long-term profitability.
Government policies on pneumonia therapeutics emphasize the development and accessibility of effective antibiotics and antiviral drugs. The Pharmaceutical Benefits Scheme (PBS) supports the affordable provision of pneumonia-related treatments to Australian citizens. Policies also aim to enhance the use of alternative treatments, including vaccines and novel therapies, to address emerging pneumonia strains and reduce the burden on the healthcare system.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Australia Pneumonia Therapeutics Market Overview |
3.1 Australia Country Macro Economic Indicators |
3.2 Australia Pneumonia Therapeutics Market Revenues & Volume, 2021 & 2031F |
3.3 Australia Pneumonia Therapeutics Market - Industry Life Cycle |
3.4 Australia Pneumonia Therapeutics Market - Porter's Five Forces |
3.5 Australia Pneumonia Therapeutics Market Revenues & Volume Share, By Type, 2021 & 2031F |
3.6 Australia Pneumonia Therapeutics Market Revenues & Volume Share, By Age Group, 2021 & 2031F |
3.7 Australia Pneumonia Therapeutics Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.8 Australia Pneumonia Therapeutics Market Revenues & Volume Share, By Drug Class, 2021 & 2031F |
3.9 Australia Pneumonia Therapeutics Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 Australia Pneumonia Therapeutics Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Australia Pneumonia Therapeutics Market Trends |
6 Australia Pneumonia Therapeutics Market, By Types |
6.1 Australia Pneumonia Therapeutics Market, By Type |
6.1.1 Overview and Analysis |
6.1.2 Australia Pneumonia Therapeutics Market Revenues & Volume, By Type, 2021- 2031F |
6.1.3 Australia Pneumonia Therapeutics Market Revenues & Volume, By Bacterial Pneumonia, 2021- 2031F |
6.1.4 Australia Pneumonia Therapeutics Market Revenues & Volume, By Viral Pneumonia, 2021- 2031F |
6.1.5 Australia Pneumonia Therapeutics Market Revenues & Volume, By Fungal Pneumonia, 2021- 2031F |
6.2 Australia Pneumonia Therapeutics Market, By Age Group |
6.2.1 Overview and Analysis |
6.2.2 Australia Pneumonia Therapeutics Market Revenues & Volume, By Children, 2021- 2031F |
6.2.3 Australia Pneumonia Therapeutics Market Revenues & Volume, By Adult, 2021- 2031F |
6.2.4 Australia Pneumonia Therapeutics Market Revenues & Volume, By Geriatric, 2021- 2031F |
6.3 Australia Pneumonia Therapeutics Market, By Route of Administration |
6.3.1 Overview and Analysis |
6.3.2 Australia Pneumonia Therapeutics Market Revenues & Volume, By Oral, 2021- 2031F |
6.3.3 Australia Pneumonia Therapeutics Market Revenues & Volume, By Parenteral, 2021- 2031F |
6.3.4 Australia Pneumonia Therapeutics Market Revenues & Volume, By Others, 2021- 2031F |
6.4 Australia Pneumonia Therapeutics Market, By Drug Class |
6.4.1 Overview and Analysis |
6.4.2 Australia Pneumonia Therapeutics Market Revenues & Volume, By Antibiotics, 2021- 2031F |
6.4.3 Australia Pneumonia Therapeutics Market Revenues & Volume, By Antiviral Drugs, 2021- 2031F |
6.4.4 Australia Pneumonia Therapeutics Market Revenues & Volume, By Antifungal Drugs, 2021- 2031F |
6.4.5 Australia Pneumonia Therapeutics Market Revenues & Volume, By Corticosteroids, 2021- 2031F |
6.4.6 Australia Pneumonia Therapeutics Market Revenues & Volume, By Others, 2021- 2031F |
6.5 Australia Pneumonia Therapeutics Market, By Distribution Channel |
6.5.1 Overview and Analysis |
6.5.2 Australia Pneumonia Therapeutics Market Revenues & Volume, By Hospital Pharmacies, 2021- 2031F |
6.5.3 Australia Pneumonia Therapeutics Market Revenues & Volume, By Retail Pharmacies, 2021- 2031F |
6.5.4 Australia Pneumonia Therapeutics Market Revenues & Volume, By Online Pharmacies, 2021- 2031F |
7 Australia Pneumonia Therapeutics Market Import-Export Trade Statistics |
7.1 Australia Pneumonia Therapeutics Market Export to Major Countries |
7.2 Australia Pneumonia Therapeutics Market Imports from Major Countries |
8 Australia Pneumonia Therapeutics Market Key Performance Indicators |
9 Australia Pneumonia Therapeutics Market - Opportunity Assessment |
9.1 Australia Pneumonia Therapeutics Market Opportunity Assessment, By Type, 2021 & 2031F |
9.2 Australia Pneumonia Therapeutics Market Opportunity Assessment, By Age Group, 2021 & 2031F |
9.3 Australia Pneumonia Therapeutics Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.4 Australia Pneumonia Therapeutics Market Opportunity Assessment, By Drug Class, 2021 & 2031F |
9.5 Australia Pneumonia Therapeutics Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 Australia Pneumonia Therapeutics Market - Competitive Landscape |
10.1 Australia Pneumonia Therapeutics Market Revenue Share, By Companies, 2024 |
10.2 Australia Pneumonia Therapeutics Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |